发明授权
US08221770B2 Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis
有权
包含来自LGTB脑膜炎奈瑟球菌的L2和/或L3免疫型脂寡糖的疫苗组合物
- 专利标题: Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis
- 专利标题(中): 包含来自LGTB脑膜炎奈瑟球菌的L2和/或L3免疫型脂寡糖的疫苗组合物
-
申请号: US12909621申请日: 2010-10-21
-
公开(公告)号: US08221770B2公开(公告)日: 2012-07-17
- 发明人: Ralph Biemans , Philippe Denoel , Christiane Feron , Carine Goraj , Jan Poolman , Vincent Weynants
- 申请人: Ralph Biemans , Philippe Denoel , Christiane Feron , Carine Goraj , Jan Poolman , Vincent Weynants
- 申请人地址: BE Rixensart
- 专利权人: GlaxoSmithKline Biologicals s.a.
- 当前专利权人: GlaxoSmithKline Biologicals s.a.
- 当前专利权人地址: BE Rixensart
- 代理商 Kathryn L. Coulter
- 优先权: GB0218035.4 20020802; GB0218036.2 20020802; GB0218037.0 20020802; GB0218051.1 20020802; GB0220197.8 20020830; GB0220199.4 20020830; GB0225524.8 20021101; GB0225531.3 20021101; GB0230164.6 20021224; GB0230168.7 20021224; GB0230170.3 20021224; GB0305028.3 20030305
- 主分类号: A61K39/05
- IPC分类号: A61K39/05
摘要:
The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are more suitable for the production of neisserial, in particular meningococcal, outer-membrane vesicle (or bleb) vaccines. Advantageous processes and vaccine products are also described based on the use of novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines which have been rendered safer and/or more effective for use in human subjects. In particular combinations of gene downregulations are described such as PorA and OpA, PorA and OpC, OpA and OpC, and PorA and OpA and OpC. Alternatively, or in addition, lgtB− is shown to be an optimal mutation for effectively and safely using L3 and/or L2 LOS in Neisseria vaccine compositions. Bleb vaccines derived from lgtB− and capsular polysaccharide deficient meningococcal mutants are further described; as are advantageous methods of making bleb preparations where LOS is to be retained as an important antigen.